Literature DB >> 655662

Dopamine binding following prolonged haloperidol pretreatment.

A Hitri, W J Weiner, R L Borison, B I Diamond, P A Nausieda, H L Klawans.   

Abstract

The number of binding sites for tritiated dopamine as well as the affinity of 3H-dopamine for dopamine receptors was studied in rats chronically pretreated with the neuroleptic haloperidol. The rats were given haloperidol for 14 or 21 days and were killed on day 21. It was found that 14 days of haloperidol pretreatment followed by drug withdrawal resulted in a 67% increase in the number of 3H-dopamine binding sites in the striatum and ninefold increase in the affinity constant in the striatum. The same pretreatment regimen had no effect on either the number of receptor sites or the affinity constant in the nucleus accumbens. These results are consistent with the hypothesis that chronic neuroleptic pretreatment results in receptor site hypersensitivity in the striatum, which may be a major factor in the production of tardive dyskinesia.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 655662     DOI: 10.1002/ana.410030208

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  11 in total

1.  Chronic low-dose haloperidol effects on self-stimulation rate-intensity functions.

Authors:  M R Lynch; R J Carey
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 2.  Antipsychotic dosing: found in translation.

Authors:  Gary Remington; Gagan Fervaha; George Foussias; Ofer Agid; Peter Turrone
Journal:  J Psychiatry Neurosci       Date:  2014-07       Impact factor: 6.186

3.  In vitro and in vivo disposition of 3H-methiothepin in brain tissues. Relationship to the effects of acute treatment with methiothepin on central serotoninergic receptors.

Authors:  D L Nelson; A Herbet; L Pichat; J Glowinski; M Hamon
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-12       Impact factor: 3.000

4.  Apomorphine-induced context-specific behavioural sensitization is prevented by the D1 antagonist SCH-23390 but potentiated and uncoupled from contextual cues by the D2 antagonist sulpiride.

Authors:  Flávia Regina Cruz Dias; Robert J Carey; Marinete Pinheiro Carrera
Journal:  Psychopharmacology (Berl)       Date:  2010-02-23       Impact factor: 4.530

5.  Treatment schedule as a determinant of the development of tolerance to haloperidol.

Authors:  R J Carey; J DeVeaugh-Geiss
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

6.  Clinical and experimental studies of phenytoin-induced hyperkinesias.

Authors:  P A Nausieda; W C Koller; W J Weiner; H L Klawans
Journal:  J Neural Transm       Date:  1979       Impact factor: 3.575

7.  Neonatal dopamine lesion in the rat results in enhanced adenylate cyclase activity without altering dopamine receptor binding or dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein (DARPP-32) immunoreactivity.

Authors:  J Luthman; E Lindqvist; D Young; R Cowburn
Journal:  Exp Brain Res       Date:  1990       Impact factor: 1.972

8.  Chronic benztropine and haloperidol administration induce behaviorally equivalent pharmacological hypersensitivities separately but not in combination.

Authors:  R J Carey; J De Veaugh-Geiss
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

9.  Increased mesolimbic dopamine binding following chronic haloperidol treatment.

Authors:  R S Kamer; A R Turi; P R Solomon; L J Kaplan
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

10.  Opposite effects of typical and atypical anti-psychotic drugs on sensitized dopamine receptors: sub-chronic low dose Olanzapine exposure reverses sensitization but a similar regimen of low dose haloperidol potentiates sensitization effects.

Authors:  Flávia Regina Cruz Dias; João Marcos de Mello Bastos; Maria de Fátima Dos Santos Sampaio; Robert J Carey; Marinete Pinheiro Carrera
Journal:  Psychopharmacology (Berl)       Date:  2013-07-12       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.